Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment

Dow Jones10-31

By Rob Curran

Aerovate Therapeutics agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other products.

After the merger, the company will trade as Jade Biosciences on the Nasdaq Composite under the ticker symbol JBIO. It will seek to develop Jade-001, a treatment for kidney condition IgA nephropathy, among other Jade drug candidates.

Jade was launched in August, the fourth company based on assets developed by Paragon Therapeutics. Jade has secured $300 million in backing for the merger from an investment consortium led by money managers Fairmount, Venrock Healthcare Capital and another unnamed firm. Prior to closing, Aerovate intends to declare a dividend, distributing cash of an estimated $65 million.

The merged biotech companies will have enough cash on hand to fund operations through 2027 and advance JADE-001 to initial clinical proof-of-concept.

In July, Aerovate had pledged to pursue strategic alternatives following the halt of a late-stage clinical trial for a blood-pressure treatment.

Shares of Aerovate rose 23% to $2.70 in premarket trading.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 31, 2024 08:40 ET (12:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479208944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-31 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479208944","market":"other","top_or_hot":-1,"title":"Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Aerovate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other products. \n</p>\n<p>\n  After the merger, the company will trade as Jade Biosciences on the Nasdaq Composite under the ticker symbol JBIO. It will seek to develop Jade-001, a treatment for kidney condition IgA nephropathy, among other Jade drug candidates. \n</p>\n<p>\n  Jade was launched in August, the fourth company based on assets developed by Paragon Therapeutics. Jade has secured $300 million in backing for the merger from an investment consortium led by money managers Fairmount, Venrock Healthcare Capital and another unnamed firm. Prior to closing, Aerovate intends to declare a dividend, distributing cash of an estimated $65 million. \n</p>\n<p>\n  The merged biotech companies will have enough cash on hand to fund operations through 2027 and advance JADE-001 to initial clinical proof-of-concept. \n</p>\n<p>\n  In July, Aerovate had pledged to pursue strategic alternatives following the halt of a late-stage clinical trial for a blood-pressure treatment. \n</p>\n<p>\n  Shares of Aerovate rose 23% to $2.70 in premarket trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 31, 2024 08:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAerovate to Merge With Jade Biosciences, Pursue Kidney Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-31 20:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Rob Curran \n\n\n \n\n\n  Aerovate Therapeutics agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479208944","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479208944","pubTimestamp":1730378400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aerovate Therapeutics agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other products.After the merger, the company will trade as Jade Biosciences on the Nasdaq Composite under the ticker symbol JBIO. It will seek to develop Jade-001, a treatment for kidney condition IgA nephropathy, among other Jade drug candidates.Jade was launched in August, the fourth company based on assets developed by Paragon Therapeutics. Jade has secured $300 million in backing for the merger from an investment consortium led by money managers Fairmount, Venrock Healthcare Capital and another unnamed firm. Prior to closing, Aerovate intends to declare a dividend, distributing cash of an estimated $65 million.The merged biotech companies will have enough cash on hand to fund operations through 2027 and advance JADE-001 to initial clinical proof-of-concept.In July, Aerovate had pledged to pursue strategic alternatives fo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AVTE":"Aerovate Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"Aerovate将与Jade Biosciences合并，追求肾脏治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVTE":0.9},"content_text":"By Rob Curran \n\n\n \n\n\n  Aerovate Therapeutics agreed to merge with privately held Jade Biosciences in an all-stock transaction, forming a company focused on a kidney-disease treatment and other products. \n\n\n  After the merger, the company will trade as Jade Biosciences on the Nasdaq Composite under the ticker symbol JBIO. It will seek to develop Jade-001, a treatment for kidney condition IgA nephropathy, among other Jade drug candidates. \n\n\n  Jade was launched in August, the fourth company based on assets developed by Paragon Therapeutics. Jade has secured $300 million in backing for the merger from an investment consortium led by money managers Fairmount, Venrock Healthcare Capital and another unnamed firm. Prior to closing, Aerovate intends to declare a dividend, distributing cash of an estimated $65 million. \n\n\n  The merged biotech companies will have enough cash on hand to fund operations through 2027 and advance JADE-001 to initial clinical proof-of-concept. \n\n\n  In July, Aerovate had pledged to pursue strategic alternatives following the halt of a late-stage clinical trial for a blood-pressure treatment. \n\n\n  Shares of Aerovate rose 23% to $2.70 in premarket trading. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 31, 2024 08:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479208944"}